Skip to content

Trial Summary

This is a Phase 1 open label study to evaluate the tolerability, safety, immunogenicity, and efficacy of SW1115C3, a neoantigen mRNA personalised cancer vaccine, in patients with advanced malignant solid tumours.



ACTRN/NCT /ethics:


Scientific title:

A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

Sponsor / Cooperative group:

Stemirna Therapeutics

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2022-03-18
Anticipated End Date2024-06-12

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead
Phone8359 2565
Principal InvestigatorA/Prof Rohit Joshi
Recruitment StatusRecruiting